Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TTP273 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| TTP273 300 mg daily (150 mg BID) | EXPERIMENTAL | Two 75 mg tablets of TTP273 administered orally twice daily for 12 weeks |
| TTP273 150 mg daily | EXPERIMENTAL | Two 75mg tablets of TTP273 administered orally once daily and two placebo tablets administered orally once daily for 12 weeks |
| Placebo | PLACEBO_COMPARATOR | Two matching placebo tablets administered orally twice daily for 12 weeks |
| Name | Type | Description |
|---|---|---|
| TTP273 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * The subject has a 6 month diagnosis of Type 2 diabetes mellitus prior to screening and meets the American Diabetes Association (ADA) guidelines for Type 2 diabetes mellitus. * On a stable regimen of metformin monotherapy equivalent to at least 1000 mg/day for the last 3 months...
TTP273 is an investigational small molecule being studied for the treatment of Type 2 Diabetes Mellitus. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
TTP273 is being developed by vTv Therapeutics Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol VTVT. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
TTP273 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is being evaluated for its safety and efficacy in patients with Type 2 Diabetes Mellitus.
TTP273 has one completed Phase 2 clinical trial, identified as NCT02653599. This was a randomized, double-blind, placebo-controlled study that enrolled 174 participants with Type 2 Diabetes Mellitus in the United States. The trial evaluated the safety and efficacy of TTP273 over a 12-week treatment period.
The specific molecular target of TTP273 has not been disclosed in available information. As a small molecule, it is designed to interact with biological pathways relevant to glucose metabolism, but the exact mechanism of action is not publicly detailed.